We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Clinical Data’s Cogenics Division Enters into Alliance with Epigenomics

Clinical Data’s Cogenics Division Enters into Alliance with Epigenomics

Clinical Data’s Cogenics Division Enters into Alliance with Epigenomics

Clinical Data’s Cogenics Division Enters into Alliance with Epigenomics

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Clinical Data’s Cogenics Division Enters into Alliance with Epigenomics"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Clinical Data, Inc. and Epigenomics AG have announced an agreement to offer Epigenomics’ DNA methylation services through Clinical Data’s service division, Cogenics.

Under this agreement, Cogenics will promote to its customers Epigenomics’ portfolio of DNA methylation services including genome-wide DNA methylation analysis, bisulfite sequencing, and real-time PCR technologies, which are performed in Epigenomics’ laboratories in Germany.

Additionally, the companies plan to offer regulated (GLP) DNA methylation analyses in Cogenics’ laboratories in the US. Under the agreement, Epigenomics will promote Cogenics’ pharmacogenomics and molecular biology services to its DNA methylation biomarker development partners and customers that Epigenomics serves through its Clinical Solutions group.

Robert Bondaryk, Ph.D., Senior Vice President and General Manager of Cogenics, said, "We are very pleased to enter into this partnership agreement with Epigenomics and look forward to working closely with the company. We are excited to offer Cogenics customers Epigenomics’ expertise and technology in DNA methylation services. This partnership brings unique value to our customers by expanding our current biomarker offering to now allow them to use DNA methylation as a marker of disease diagnosis, prognosis and drug response prediction.”

Christina Dahlstroem, Ph.D., Senior Vice President of Epigenomics’ Clinical Solutions group, said, “This reference laboratory partnership with Cogenics enables us to serve Cogenics’ broad client base with our DNA methylation services and biomarker development expertise.”

“We are excited about the prospect of eventually offering DNA methylation analysis in a regulated environment through Cogenics. This will be particularly important once our pharma partners want to use the biomarkers in clinical trials. In addition, we are enthusiastic about being able to offer our customers an even broader range of biomarker services, in addition to DNA methylation, through this partnership with Cogenics,” Dahlstroem added.